Gonzalo Laje

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Genetic markers of suicidal ideation emerging during citalopram treatment of major depression
    Gonzalo Laje
    Genetic Basis of Mood and Anxiety Disorders, NIMH, 35 Convent Dr, Rm 1A207, Bethesda, MD 20892 3719, USA
    Am J Psychiatry 164:1530-8. 2007
  2. ncbi The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort
    Magnus Lekman
    Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
    Biol Psychiatry 63:1103-10. 2008
  3. ncbi Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB
    Gonzalo Laje
    Unit on the Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, Bethesda, MD 20892 3719, USA
    Int J Neuropsychopharmacol 13:715-24. 2010
  4. ncbi Pharmacogenetics studies in STAR*D: strengths, limitations, and results
    Gonzalo Laje
    Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health, Bethesda, MD 20892, USA
    Psychiatr Serv 60:1446-57. 2009
  5. ncbi Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients
    Gonzalo Laje
    Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Pharmacogenet Genomics 19:666-74. 2009
  6. ncbi Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome
    Gonzalo Laje
    Intramural Research Program at the National Institute of Mental Health, NIH, Bethesda, MD 20892 3719, USA
    Am J Med Genet C Semin Med Genet 154:463-8. 2010
  7. ncbi Genome-wide association studies of antidepressant outcome: a brief review
    Gonzalo Laje
    Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, NIH, US DHHS, Bethesda, MD, United States
    Prog Neuropsychopharmacol Biol Psychiatry 35:1553-7. 2011
  8. ncbi Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort
    Silvia Paddock
    Genetic Basis of Mood and Anxiety Disorders, Mood and Anxiety Program, NIMH, NIH, Department of Health and Human Services, Bethesda, MD, USA
    Am J Psychiatry 164:1181-8. 2007
  9. ncbi Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment
    Francis J McMahon
    Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health NIMH, National Institutes of Health, Bethesda, MD 20892 3719, USA
    Am J Hum Genet 78:804-14. 2006
  10. ncbi Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression
    Xian Zhang Hu
    Section on Molecular Genetics, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 64:783-92. 2007

Detail Information

Publications22

  1. ncbi Genetic markers of suicidal ideation emerging during citalopram treatment of major depression
    Gonzalo Laje
    Genetic Basis of Mood and Anxiety Disorders, NIMH, 35 Convent Dr, Rm 1A207, Bethesda, MD 20892 3719, USA
    Am J Psychiatry 164:1530-8. 2007
    ..Genetic markers may shed light on the causes of treatment-emergent suicidal ideation and help identify individuals at high risk who may benefit from closer monitoring, alternative treatments, or specialty care...
  2. ncbi The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort
    Magnus Lekman
    Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
    Biol Psychiatry 63:1103-10. 2008
    ..The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram...
  3. ncbi Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB
    Gonzalo Laje
    Unit on the Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, Bethesda, MD 20892 3719, USA
    Int J Neuropsychopharmacol 13:715-24. 2010
    ....
  4. ncbi Pharmacogenetics studies in STAR*D: strengths, limitations, and results
    Gonzalo Laje
    Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health, Bethesda, MD 20892, USA
    Psychiatr Serv 60:1446-57. 2009
    ..Replication of these findings in independent samples could lead to the development of new treatments and to optimization of available treatments...
  5. ncbi Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients
    Gonzalo Laje
    Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Pharmacogenet Genomics 19:666-74. 2009
    ....
  6. ncbi Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome
    Gonzalo Laje
    Intramural Research Program at the National Institute of Mental Health, NIH, Bethesda, MD 20892 3719, USA
    Am J Med Genet C Semin Med Genet 154:463-8. 2010
    ..Although no medication category was identified as efficacious in SMS, all the categories reported herein may be considered as an option for brief symptomatic relief...
  7. ncbi Genome-wide association studies of antidepressant outcome: a brief review
    Gonzalo Laje
    Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, NIH, US DHHS, Bethesda, MD, United States
    Prog Neuropsychopharmacol Biol Psychiatry 35:1553-7. 2011
    ..This review discusses the published GWAS studies, their strengths, limitations, and possible future directions...
  8. ncbi Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort
    Silvia Paddock
    Genetic Basis of Mood and Anxiety Disorders, Mood and Anxiety Program, NIMH, NIH, Department of Health and Human Services, Bethesda, MD, USA
    Am J Psychiatry 164:1181-8. 2007
    ..The purpose of the present study was to utilize a second wave of genotype results, for a more powerful analysis, in the complete cohort of patients with available deoxyribonucleic acid (DNA) samples...
  9. ncbi Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment
    Francis J McMahon
    Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health NIMH, National Institutes of Health, Bethesda, MD 20892 3719, USA
    Am J Hum Genet 78:804-14. 2006
    ..Taken together with prior neurobiological findings, these new genetic data make a compelling case for a key role of HTR2A in the mechanism of antidepressant action...
  10. ncbi Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression
    Xian Zhang Hu
    Section on Molecular Genetics, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 64:783-92. 2007
    ....
  11. ncbi Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder
    Jessica A Cutler
    Genetic Basis of Mood and Anxiety Disorders Unit, National Institute of Mental Health, Bethesda, MD 20892 3719, USA
    J Psychopharmacol 26:360-7. 2012
    ..We conclude that common genetic variation in IDO1 and IDO2 may play a role in antidepressant treatment outcome. These results are modest in a genome-wide context and need to be replicated in an independent sample...
  12. ncbi Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Psychiatry 72:331-8. 2012
    ..Ketamine is extensively metabolized. This study examined the relationship between ketamine metabolites and response, diagnosis, and psychotomimetic symptoms in MDD and BD patients...
  13. ncbi Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample
    Michael Cabanero
    Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 3719, USA
    Pharmacogenet Genomics 19:235-8. 2009
    ..We conclude that PDE11A, PDE9A, and PDE1A are unlikely to play an important role in antidepressant outcome in this sample...
  14. ncbi The pharmacogenetics of major depression: past, present, and future
    Gonzalo Laje
    Genetic Basis of Mood and Anxiety Disorders Unit, Mood and Anxiety Program, National Institute of Mental Health, Bethesda, MD 20892, USA
    Biol Psychiatry 62:1205-7. 2007
  15. ncbi Autism spectrum features in Smith-Magenis syndrome
    Gonzalo Laje
    Intramural Research Program at the National Institute of Mental Health, NIH, Bethesda, MD 20892 1851, USA
    Am J Med Genet C Semin Med Genet 154:456-62. 2010
    ..The mechanisms by which the deletion of RAI1 and contiguous genes cause psychopathology remain unknown but they provide a solid starting point for further studies of gene-brain-behavior interactions in SMS and autism spectrum disorders...
  16. ncbi The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment
    Thomas G Schulze
    Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 3719, USA
    Neuropsychobiology 62:72-8. 2010
    ..A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts...
  17. ncbi The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations
    Johannes Schumacher
    Unit on the Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD 20892 3719, USA
    Hum Mol Genet 18:2719-27. 2009
    ..Furthermore, our phenotype-genotype results--including the consideration of sex-specific effects--highlight the value of homogenous samples in mapping risk genes for schizophrenia in general, and at the DISC locus in particular...
  18. ncbi The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder
    Rodrigo Machado-Vieira
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 69:344-52. 2011
    ..Here, we examined the effects of the Bcl-2 gene single nucleotide polymorphism (SNP) rs956572 on intracellular Ca(2+) dynamics in patients with BPD...
  19. ncbi National trends in the outpatient diagnosis and treatment of bipolar disorder in youth
    Carmen Moreno
    Unidad de Adolescentes, Hospital General Universitario Gregorio Maranon, Servicio do Psiquiatría, Madrid, Spain
    Arch Gen Psychiatry 64:1032-9. 2007
    ..Although bipolar disorder may have its onset during childhood, little is known about national trends in the diagnosis and management of bipolar disorder in young people...
  20. ncbi Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study
    Yujuan Choy
    Freedom from Fear, Staten Island, NY 10305, USA
    Compr Psychiatry 48:419-25. 2007
    ..The purpose of this naturalistic study is to compare outcomes of remitted panic disorder patients continued on versus those successfully discontinued from maintenance medication...
  21. ncbi National trends in the outpatient treatment of children and adolescents with antipsychotic drugs
    Mark Olfson
    New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arch Gen Psychiatry 63:679-85. 2006
    ..Although there are indications that antipsychotic drugs are increasingly used to treat children and adolescents, little is known about the characteristics of those who receive them...
  22. ncbi Trends in the treatment of bipolar disorder by outpatient psychiatrists
    Carlos Blanco
    Department of Psychiatry and New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Am J Psychiatry 159:1005-10. 2002
    ..This study examined recent changes in the prescribing patterns for medications to treat bipolar disorder in office-based psychiatric practice...